Published Date: Feb-19
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Asia Pacific Cartilage Repair Market, published by KBV research, the Asia Pacific Cartilage Repair Market would witness market growth of 9.8% CAGR during the forecast period (2018 – 2024).
The Japan market would dominate the Asia Pacific Knee Cartilage Repair Market by Country by 2024, growing at a CAGR of 8.4 % during the forecast period. The China market is expected to witness a CAGR of 8.7% during (2018 - 2024). Additionally, The India market is expected to witness a CAGR of 11.2% during (2018 - 2024).
The Intrinsic Repair Stimulus market dominated the Asia Pacific Cartilage Repair Market by Treatment Type in 2017. The Palliative market is expected to witness highest CAGR of 10.5% during (2018 - 2024).
The Cell-Based market dominated the South Korea Cartilage Repair Market by Modality, 2018 - 2024, USD Million in 2017, and would achieve a market value of $90.2 million by 2024, growing at a CAGR of 9.5 % during the forecast period. Additionally, The Non-Cell-Based market is expected to witness highest CAGR of 11% during (2018 - 2024).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of B. Braun Melsungen AG, Zimmer Biomet, Johnson and Johnson, Smith & Nephew Plc., Stryker Corporation, Vericel Corporation, Osiris Therapeutics Inc., Arthrex, Inc., Collagen Solutions Plc., and Anika Therapeutics, Inc.
Asia Pacific Cartilage Repair Market Segmentation
By Treatment type
By Site outlook
Unique Offerings from KBV Research